Ramos-Rincon, Jose ManuelPerez-Belmonte, Luis MCarrasco-Sanchez, Francisco JavierJansen-Chaparro, SergioDe-Sousa-Baena, MercedesBueno-Fonseca, JosePerez-Aguilar, MariaArevalo-Cañas, CoralBacete-Cebrian, MartaMendez-Bailon, ManuelFiteni-Mera, IsabelGonzalez-Garcia, AndresNavarro-Romero, FranciscoTuñon-de-Almeida, CarlotaMuñiz-Nicolas, GemmaGonzalez-Noya, AmaraHernandez-Milian, AlmudenaGarcia-Garcia, Gema MariaAlcala-Pedrajas, Jose NicolasHerrero-Garcia, VirginiaCorral-Gudino, LuisComas Casanova, PereMeijide-Miguez, HectorCasas-Rojo, Jose ManuelGomez-Huelgas, Ricardo2023-02-092023-02-092021-05-04Ramos-Rincón JM, Pérez-Belmonte LM, Carrasco-Sánchez FJ, Jansen-Chaparro S, De-Sousa-Baena M, Bueno-Fonseca J, et al. Cardiometabolic Therapy and Mortality in Very Old Patients With Diabetes Hospitalized due to COVID-19. J Gerontol A Biol Sci Med Sci. 2021 Jul 13;76(8):e102-e109http://hdl.handle.net/10668/17741The effects of cardiometabolic drugs on the prognosis of diabetic patients with COVID-19, especially very old patients, are not well known. This work was aimed to analyze the association between preadmission cardiometabolic therapy (antidiabetic, antiaggregant, antihypertensive, and lipid-lowering drugs) and in-hospital mortality among patients ≥80 years with type 2 diabetes mellitus (T2DM) hospitalized for COVID-19. We conducted a nationwide, multicenter, observational study in patients ≥80 years with T2DM hospitalized for COVID-19 between March 1 and May 29, 2020. The primary outcome measure was in-hospital mortality. A multivariate logistic regression analysis was performed to assess the association between preadmission cardiometabolic therapy and in-hospital mortality. Of the 2 763 patients ≥80 years old hospitalized due to COVID-19, 790 (28.6%) had T2DM. Of these patients, 385 (48.7%) died during admission. On the multivariate analysis, the use of dipeptidyl peptidase-4 inhibitors (adjusted odds ratio [AOR] 0.502, 95% confidence interval [CI]: 0.309-0.815, p = .005) and angiotensin receptor blockers (AOR 0.454, 95% CI: 0.274-0.759, p = .003) were independent protectors against in-hospital mortality, whereas the use of acetylsalicylic acid was associated with higher in-hospital mortality (AOR 1.761, 95% CI: 1.092-2.842, p = .020). Other antidiabetic drugs, angiotensin-converting enzyme inhibitors, and statins showed neutral association with in-hospital mortality. We found important differences between cardiometabolic drugs and in-hospital mortality in older patients with T2DM hospitalized for COVID-19. Preadmission treatment with dipeptidyl peptidase-4 inhibitors and angiotensin receptor blockers could reduce in-hospital mortality; other antidiabetic drugs, angiotensin-converting enzyme inhibitors, and statins seem to have a neutral effect; and acetylsalicylic acid could be associated with excess mortality.enAge ≥ 80Cardiometabolic therapyCoronavirus disease-2019MortalityType 2 diabetesÁrea Sanitaria Norte de CórdobaAged, 80 and overAngiotensin Receptor AntagonistsCOVID-19Cardiovascular DiseasesDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsFemaleHospital MortalityHospitalizationHumansHypoglycemic AgentsMaleSARS-CoV-2research article33945610Restricted AccessMortalidad HospitalariaHipoglucemiantesAspirinaInhibidores de la Enzima Convertidora de AngiotensinaInhibidores de Hidroximetilglutaril-CoA ReductasasAntagonistas de Receptores de Angiotensina10.1093/gerona/glab1241758-535XPMC8135901https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8135901https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8135901/pdf